Mibenratide

Drug Profile

Mibenratide

Alternative Names: COR-1; JNJ-54452840

Latest Information Update: 16 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Corimmun
  • Developer Corimmun; Janssen-Cilag
  • Class Cyclic peptides; Disulfides; Heart failure therapies; Peptides
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 18 Sep 2015 No recent reports on development identified - Phase-I for Heart failure (In volunteers) in USA (IV)
  • 18 Sep 2015 No recent reports on development identified - Phase-II for Heart failure in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top